Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Neoplasm Metastasis
Interventions: DRUG: Non pegylated liposomal doxorubicin, trastuzumab, docetaxel
Sponsor: Laurence J.C. van Warmerdam
Collaborators: Cephalon|Sanofi